| http://www.w3.org/ns/prov#value | - didate for Pfizer to jump-start its new generic drug strategy.Small-Cap Stocks, Big FDA DecisionsCypress Bio (CYPB) and partner Forest Labs (FRX) have a pending FDA decision for milnacipran in the treatment of fibromyalgia, which has been widely used as an anti-depressant in Europe and other markets for over a decade.
|
